What We’re Reading: Abortion Pill Access Arguments; Clinical Research Site Inspections; AstraZeneca 340B Lawsuit
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.